2-PAM Autoinjectors Project Bioshield

Back to opportunities

Pre-SolNo Set aside used

2-PAM Autoinjectors Project Bioshield

HEALTH AND HUMAN SERVICES, DEPARTMENT OF › BARDA - ASPR / DAAPPO / BARDA DCMA

Posted Jun 2, 2026

Due Jun 16, 2026

Washington, DC

NAICS 541714

Sol # 75A50126R00002

AI Summary

• BARDA seeks late-stage clinical development and regulatory approval for 2-PAM autoinjectors as a drug/device combination product to treat organophosphate poisoning.
• This is an unrestricted full and open competition relevant to NAICS 321940 (Drug Research and Test Services).
• Clinical trials will focus on adult and pediatric populations with a procurement component targeting the SNS/CHEMPACK Program.

Description

This is a presoliciation notice for the following: BARDA seeks late-stage clinical development, regulatory approval for 2-PAM autoinjectors (as a drug/device combination product) to treat organophosphate (OP) poisoning, including nerve agents, in adult and pediatric populations, and procurement of 2-PAM autoinjectors for the SNS/CHEMPACK Program.

Classification

NAICS541714

PSC CodeAB12

Place of Performance

CityWashington

StateDC

ZIP20024

CountryUNITED STATES

Contracting Office

OfficeBARDA - ASPR / DAAPPO / BARDA DCMA

CityWASHINGTON

StateDC

ZIP20515

Contacts

Erin Greninger, Contracting Officer

erin.greninger@hhs.gov

Greg Smith(secondary)

greg.smith1@hhs.gov